Wheeler Benjamin Richard 4

What Happened

• Benjamin R. Wheeler, Chief Financial Officer of Myriad Genetics (MYGN), was granted 4,994 performance-based restricted stock units (PSUs) on February 2, 2026. The reported acquisition price is $0.00 and the grant is recorded as an award, not a purchase or sale.
• Per the filing footnote, these PSUs were part of an initial grant on March 15, 2023 and the Compensation and Human Capital Committee certified the final award amount on Feb 2, 2026. Each PSU is a contingent right to one share and vests on March 15, 2026 if performance metrics are met.

Key Details

• Transaction date: 2026-02-02; Filing date (Form 4): 2026-02-03 (timely).
• Transaction type/code: Award/Grant (A); 4,994 PSUs granted at $0.00 (no cash paid).
• Shares owned after transaction: Not specified in the provided filing data.
• Footnote: PSUs are performance-based, initially granted 3/15/2023; Committee determined final payout 2/2/2026; vesting on 3/15/2026 subject to achievement of preset metrics.
• No indication of a 10b5-1 plan, tax-withholding sale, or late filing in the reported data.

Context

• PSUs are compensation awards that convert into common shares only if performance conditions and vesting requirements are satisfied; they do not represent immediate market purchases or sales.
• Such awards are routine executive compensation and shouldn't be interpreted as an outright buy or sell signal by themselves — they reflect pay tied to performance targets and retention.